Blue Jet Healthcare to Launch INR 2,300-Cr Pharma Plant in Andhra Pradesh

Blue Jet Healthcare to Launch INR 2,300-Cr Pharma Plant in Andhra Pradesh

India’s Contrast Media Intermediates Major Blue Jet Healthcare to Break Ground Tomorrow on INR 2,300-Crore Mega Pharma Plant in Andhra Pradesh

Chandigarh, Feb 28: Blue Jet Healthcare Ltd, one of India’s leading manufacturers of contrast media intermediates used in medical imaging, will tomorrow break ground on a ₹2,300-crore greenfield pharmaceutical manufacturing facility at Rambilli Industrial Park in Anakapalli district, marking a significant scale-up of India’s specialty pharma and CDMO capabilities.

Spread across over 102 acres near Visakhapatnam, the project will create new production capacities for contrast media intermediates, high-intensity sweeteners and multipurpose chemistry units. The facility will be developed in phases and is targeted to become operational by FY2028–29.

From 1968 chemicals firm to global CDMO

Founded in 1968 as Jet Chemicals Private Limited, Blue Jet Healthcare has evolved into a science-led specialty pharmaceutical and healthcare ingredients company headquartered in Maharashtra.

Today, it operates as an integrated Contract Development and Manufacturing Organisation (CDMO), supplying advanced pharmaceutical intermediates, APIs, contrast media intermediates and high-intensity sweeteners to customers across India, Europe, the United States and other international markets. The company is recognised as one of India’s leading players in contrast media intermediates and an early pioneer of saccharin manufacturing in the country.

Over decades, it has built deep expertise in process chemistry, manufacturing scale-up and global regulatory-compliant production, positioning itself as a strategic supplier to multinational pharmaceutical companies.

Scale, sustainability and supply-chain depth

The Rambilli project entails an investment of approximately ₹2,300 crore and is expected to generate 1,750 direct jobs and 250 indirect jobs, significantly strengthening the industrial profile of the Visakhapatnam economic region.

Importantly, the facility will integrate an advanced Effluent Treatment Plant (ETP) with marine discharge connectivity and incorporate Zero Liquid Discharge (ZLD) technologies. According to the company profile, this system is designed to enable a 70% reduction in energy consumption while recovering 90–95% of wastewater a critical factor as global pharma supply chains tighten ESG and compliance benchmarks.

The investment is expected to deepen India’s domestic manufacturing base in high-value specialty intermediates at a time when global pharmaceutical companies are increasingly diversifying supply chains beyond single geographies.

Leadership driving expansion

The company is led by Executive Chairman Akshay Bansarilal Arora, who has been associated with the business for over four decades and has served on the Board since 1983. With academic training in chemistry and extensive experience in specialty chemicals and pharma, he has been instrumental in transforming Blue Jet into a global supplier of contrast media intermediates and niche pharmaceutical products.

Managing Director Shiven Akshay Arora, who joined the Board in 2015, oversees expansion initiatives and global strategy, with a focus on modernization, innovation and Greenfield developments.

Andhra’s pharma cluster ambitions

For Andhra Pradesh, the ground breaking signals further momentum in its cluster-based industrial push, particularly in pharmaceuticals and bulk drugs. The Rambilli Industrial Park is being positioned as a hub for high-value chemical and pharma manufacturing along the eastern coast.

For Blue Jet Healthcare, the project represents a decisive step in scaling its global CDMO footprint reinforcing India’s ambition to move up the pharmaceutical value chain from generics to complex intermediates and specialty chemistry.

The coconut will be broken tomorrow, but strategically, this is a long-term bet on India’s chemistry, on global supply-chain realignment, and on specialty pharma scale from the eastern seaboard.